Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — FY2025 Earnings Presentation
22 slides from Wuxi Apptec Co., Ltd. Class A's earnings presentation, Mar 24, 2026
Slide 1: WuXi AppTec 2025 Annual Results
WuXi AppTec 2025 Annual Results March 24, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Results Overview, Segment Performance, Financial Performance, Company Outlook
01 Results Overview 02 Segment Performance 03 Financial Performance 04 Company Outlook 3 Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRS. The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to t
Slide 4: 1. Results Overview
1. Results Overview WW) Birtec
Slide 5: 2025 Revenue & Profit Both Reached Record Highs
2025 Revenue & Profit Both Reached Record Highs, Revenue from Continuing Operations Up 21.4% YoY, and Adjusted Non-IFRS Net Profit Up 41.3% YoY Revenue Adjusted Non-IFRS Net Profit RMB billion RMB billion Adjusted Non-IFRS NPM Discontinued Operations Continuing Operations +15.8% +21.4%1 +41.3% Reven
Slide 6: Backlog for Continuing Operations Up 28.8% YoY
With Continuous Capacity Expansion to Better Meet Customer Demand, Backlog for Continuing Operations1 Up 28.8% YoY as of December 31, 2025 Backlog for Continuing Operations1 RMB billion +28.8% 58.00 56.26 53.04 48.36 45.04 37.44 38.59 31.42 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4
Slide 7: Diversified Revenue Streams Across Regions
Diversified Revenue Streams of Continuing Operations from Customers Across Regions Underpin the Stability and Resilience of the Company’s Business Performance RMB billion China Europe 5.47Bn, -3.5% 4.82Bn, -4.0% Revenue contribution: 13% Revenue contribution: 11% US 31.25Bn, +34.3% Revenue contribut
Slide 8: Driving Sustainability, Embracing Initiatives
Driving Sustainability, Embracing Initiatives, Sustained Recognition by Leading Global Ratings Achieved “AAA” from MSCI, “A” from CDP Climate Change & Water Security, and “Gold” from EcoVadis in 2025; Near-term GHG Emissions Reduction Targets Validated by SBTi Received first MSCI “AAA” rating Improv
Slide 9: Safeguarding Customers' IP and Quality Compliance
Unwavering Commitment to Safeguarding Customers’ IP and Adhering to the Highest Standards of Quality & Compliance 741 60 Quality Audits & Inspections1 by Information Security Global Customers, Regulatory Audits by Global Authorities & Third Parties (2025) Customers (2025) 0 20 Main Sites2 are ISO/IE
Slide 10: 2. Segment Performance
2. Segment Performance WW) Bertec
Slide 11: WuXi Chemistry Revenue Up 25.5% YoY
WuXi Chemistry: CRDMO Business Model Drives Continuous Growth; 2025 Revenue Up 25.5% YoY, with TIDES Revenue Up 96.0% YoY Revenue & Gross Profit Margin CRDMO Business Model Drives Continuous Growth ⚫ 2025 WuXi Chemistry revenue up 25.5% YoY to 36.47bn RMB billion ⚫ With continued optimization of pro
Slide 12: Small Molecule CRDMO Pipeline
WuXi Chemistry: “Follow the Molecule + Win the Molecule”, Small Molecule CRDMO Pipeline Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth “R” 420,000+compounds 14,751 Compounds 2025 Newly Added Molecules to D&M Pipeline in Total 839 2,901 Preclinical & Phase I “D”
Slide 13: TIDES Continued Rapid Business Growth
TIDES: Continued Rapid Business Growth Driven by Enhanced Capabilities and Capacity TIDES Revenue Solid Phase Peptide Synthesizer Total Reactor Volume RMB billion Liter >100,000 +96% 11.37 41,000 5.80 32,000 3.41 2.04 0.79 4,000 6,000 0.30 500 2,000 2020 2021 2022 2023 2024 2025 2019 2020 2021 2022
Slide 14: WuXi Testing Revenue Back to Positive Growth
WuXi Testing1: Strengthening Differentiated Capabilities and Operational Management; 2025 Revenue Back to Positive YoY Growth of 4.7%, Drug Safety Evaluation Services Maintained Leading Position Revenue & Gross Profit Margin1 RMB billion ⚫ 2025 WuXi Testing1 revenue resumed positive growth, up 4.7%
Slide 15: WuXi Biology Revenue Back to Positive Growth
WuXi Biology: Continues to Follow the Science & Generate Downstream Opportunities; 2025 Revenue Back to Positive YoY growth of 5.2%, In Vivo & In Vitro Synergies and New Modalities Drove Growth Revenue & Gross Profit Margin ⚫ WuXi Biology follows the science and strategically builds differentiated R
Slide 16: 3. Financial Performance
3. Financial Performance WW) Bertec
Slide 17: Enhanced Profitability Across 2020 to 2025
Continuously Drive Quality Growth, Strengthen Technological Expertise and Operational Efficiency, Leverage Management Resilience, Further Enhancing Profitability Adjusted Non-IFRS Gross Profit Adjusted Non-IFRS GPM* Adjusted Non-IFRS Net Profit Adjusted Non-IFRS NPM RMB billion RMB billion 40.3% 38.
Slide 18: 2025 Adjusted Operating Cash Flow Reached Record High
With Sustained Business Growth, Enhanced Operational Efficiency and Financial Management, 2025 Adjusted Operating Cash Flow1 Reached Record High of 16.67 Billion, Up 39.1% YoY RMB billion 16.67 Adjusted Operating Cash Flow1 Capex2 12.64 11.99 9.97 10.23 6.94 5.52 5.54 4.38 4.00 3.83 3.03 2020 2021 2
Slide 19: 4. Company Outlook
4. Company Outlook WW) Bertec
Slide 20: Company Outlook
Company Outlook Focus on the CRDMO business model, striving for highly efficient & exceptional services and operational excellence ("O") ⚫ Continue to focus on our unique integrated CRDMO core business, and accelerate global expansion, capacity construction and capability development ⚫ Leveraging cu
Slide 21: Cash Dividend Distribution Plan in 2026
Company Outlook Remain committed to rewarding shareholders and upholding the Company's value ⚫ While accelerating global capacity and capability enhancement, the Company’s Board of Directors proposes (subject to approval by the Annual General Meeting) the cash dividend distribution plan in 2026, tot
Slide 22: WuXi AppTec
Wuxi AppTec